Clinical presentation and results of thrombolytis therapy in older patients with massive pulmonary embolism: A comparison with non-elderly patients;Comparaison de l'efficacite et de la tolerance d'un traitement thrombolytique par rt-PA dans l'embolie pulmonaire aigue massive chez le sujet age etchez les moins de 75 ans

Revue de Medecine Interne

Volumn 18, Issue 7, 1997, Pages 521-527

  Gisselbrecht, M ^a   Diehl, J L ^a   Meyer, G ^a   Sors, H ^a  

^a Hopital Laennec   (France)

Author keywords

Elderly; Pulmonary embolism; Thrombolytic treatment

Indexed keywords

ALTEPLASE; PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; AGING; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; TREATMENT INDICATION; ACUTE DISEASE; AGE; COMPARATIVE STUDY; FIBRINOLYTIC THERAPY; FOLLOW UP; HOSPITALIZATION; MIDDLE AGED; MORTALITY; RISK FACTOR;

ACUTE DISEASE; ADULT; AGE FACTORS; AGED; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATORS; PULMONARY EMBOLISM; RISK FACTORS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030740324     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(97)80803-X     Document Type: Article

References (30)

1. Lilienfeld DE, Godbold JH, Burke GL et al. Hospitalization and case fatality for pulmonary embolism in the twin cities: 1979-1984. Am Heart J 1990;120:392-5
2. Impallomeni MG, Arnot RN, Alexander MSM et al. Incidence of pulmonary embolism in elderly patients newly admitted to an acute geriatric unit: a prospective study. Clin Nucl Med 1990;15:84-7
3. Meneveau N, Bassand JP, Schiele F et al. Safety of thrombolytic therapy in elderly patients with massive pulmonary embolism: a comparison with nonelderly patients. J Am Coll Cardiol 1993;22:1075-9
4. Goldhaber SZ, Haire WD, Feldstein ML et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993;341:507-11
5. Meyer G, Sors H, Stern M et al. Thrombolysis in acute pulmonary embolism. In: Julian D, ed. Thrombolysis in cardiovascular disease. New York: Marcel Dekker, 1989:337-60
6. Kelton JG, Hirsh J. Bleeding associated with antithrombotic therapy. Semin Hematol 1980;7:259-91
7. Chaitman BR, Thompson B, Wittry MD et al. The use of tissue-type plasminogen activator for acute myocardial infarction in the elderly: results from thrombolysis in myocardial infarction phase I, open label studies and the thrombolysis in myocardial infarction phase II pilot study. J Am Coll Cardiol 1989;14:1159-65
8. Lew AS, Hod H, Cercek B et al. Mortality and morbidity rates of patients older and younger than 75 years with acute myocardial infarction treated with intravenous streptokinase. Am J Cardiol 1987;59:1-5
9. Goldhaber SZ. Tissue plasminogen activator in acute pulmonary embolism. Chest 1989;95:282S-289S
10. Diehl JL, Meyer G, Igual J et al. Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism. Am J Cardiol 1992;70:1477-80
11. Miller GAH, Sutton GC, Kerr IH et al. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Med J 1971;2:681-4
12. Meyer G, Collignon MA, Guinet F et al. Comparison of perfusion lung scanning and angiography in the estimation of vascular obstruction in acute pulmonary embolism. Eur J Nucl Med 1990;17:315-9
13. Coon WW, Willis PW, Keller JB. Venous thromboembolism and other venous disease in the Tecumseh community health study. Circulation 1973;48:839-46
14. Anderson FA, Wheeler HB, Goldberg RJ et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991;151:933-8
15. Coon WW, Coller FA. Some epidemiologic considerations of thromboembolism. Surg Gynecol Obstet 1959;109: 487-501
16. Coon WW. Venous thromboembolism: prevalence, risk factors and prevention. Clin Chest Med 1984;5:391-401
17. Gold G, Pervez N, Kropsky B et al. Pulmonary embolism in the nursing home population: high frequency at autopsy in female residents. Arch Gerontol Geriatr 1992;14: 117-22
18. Lilienfeld DE, Chan E, Ehland J et al. Mortality from pulmonary embolism in the United States: 1962 to 1984. Chest 1990;98:1067-72
19. Sigel B, Justin JR, Gibson RJ et al. Risk assessement of pulmonary embolism by multivariate analysis. Arch Surg 1979;114:188-92
20. Goldhaber SZ, Savage DD, Garrison RJ et al. Risk factors for pulmonary embolism: the Framingham study. Am J Med 1983;74:1023-8
21. Mangion DM. Pulmonary embolism - incidence and prognosis in hospitalized elderly. Postgrad Med J 1989;65:814-7
22. Busby W, Bayer A, Pathy G. Pulmonary embolism in the elderly. Age Ageing 1988;17:205-9
23. Stein PD, Gottschalk A, Saltzman HA, Terrin ML. Diagnosis of acute pulmonary embolism in the elderly. J Am Coll Cardiol 1991;18:1452-7
24. The Urokinase Pulmonary Embolism Trial: A national cooperative study. Circulation 1973;47:II-1-108
25. Levine MN, Hirsh J, Weitz J et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990;98:1473-9
26. Thrombolytic therapy in thrombosis: a National Institutes of Health consensus development conference. Ann Intern Med 1980;93:141-41
27. Anderson HV, Willerson JT. Thrombolysis in acute myocardial infarction. N Engl J Med 1993;329:703-9
28. Krumholz HM, Pasternak RC, Weinstein MC et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992;327:7-13
29. Topol EJ, Califf RM. Thrombolytic therapy for elderly patients. N Engl J Med 1992;327:45-7
30. Califf RM, Topol EJ, George BS et al. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. Am J Med 1988;85:353-9